GUEST COMMENTARY | FROM Page 17 ed States. Many more live with PTSD and depression that existing treatments fail to address. These are stubborn, complex conditions. Many veterans spend years cycling through medications, therapy programs, and referrals with little meaningful relief. It has been more than 25 years since the United States has approved a new treatment for PTSD. With conventional treatments failing, some veterans are traveling overseas to access psychedelic-assisted treatments being used abroad. Veterans are navigating unfamiliar providers and inconsistent standards because they believe these treatments may off er their best chance at recovery. But seeking care abroad comes with a lot of risks. For starters, it’s harder to verify if a provider has a legitimate medical license or credentials. Many of these clinics operate outside the oversight and safeguards of the U.S. medical system. As CBS News has reported, there are no standardized health screenings before treatment, required monitoring protocols, or requirements to track adverse eff ects. That wouldn’t be the case on American soil. It is time to create a safe, regulated pathway for veterans to access these medicines within the protections of the American medical system. For decades, skepticism surrounding psychedelic compounds largely shut down research in the United States. But over the past twenty years, that has begun to change. Major academic institutions have restarted carefully controlled clinical studies. Governments and regulators are beginning to respond. In 2023, Australia became the fi rst country to permit limited clinical use of MDMA and psilocybin under strict psychiatric supervision. U.S. policymakers have recently shown greater openness to expanding psychedelic research. The clinical evidence continues to grow. Psilocybin medicine has produced rapid reductions in symptoms of major depression. MDMA-assisted treatment has shown substantial reductions in PTSD symptoms. In one trial, 67% of participants no longer met the diagnostic criteria for PTSD after treatment. - LEGAL NOTICE - COMMONWEALTH OF MASSACHUSETTS PROBATE AND FAMILY COURT DEPARTMENT SUFFOLK DIVISION, ss Docket No. SU25P2209PM SALE OF REAL ESTATE MAINTENANCE To all persons interested in the estate of MARILYN J. BROWN of REVERE, MA in said County, person under conservatorship single. A petition has been presented to said Court for license to sell at private sale - certain real estate of said MARILYN J. BROWN for her maintenance. a written appearance in said Court at Court, Boston before ten o’clock in the forenoon on the 30th day of July 2026, the return day of this citation. Witness, Hon. Janine D. Rivers, Esquire, First Judge of said Court this 25th day of June 2026. STEPHANIE L. EVERETT REGISTER OF PROBATE July 03, 10, 17, 2026 For Advertising with Results, call The Advocate Newspapers at 781-286-8500 or Info@advocatenews.net THE REVERE ADVOCATE – FRIDAY, JULY 17, 2026 These treatments are being Page 19 held to the same scientifi c and regulatory standards applied to any other medicine seeking approval. Nothing should move forward without rigorous FDA review. But if research continues to demonstrate strong results, veterans should not be forced to leave the country to access care that may help them heal. Veterans are already seeking these treatments. The real question is where — and under what conditions — they receive them. They deserve the safest option. Aaron Q. Seibert serves as a Wounded Warrior Liaison, host of the “Combat Vet Vision” podcast, vice president of the Warrior Built Foundation, and heads the West Coast offi ces of the PTSD Foundation of America. He served three combat tours as a Navy Corpsman and is the recipient of a Purple Heart. A version of this piece originally ran in Townhall. The World’s First Hearing Aids With Touchscreen Controls. No tiny buttons. No apps. No prescriptions. Call 844-497-3476 to get your 45-day risk free trial. Revolutionary technology with touchscreen control. Hearing modes for any environment. Multiple models to choose from. Portable charging case. 48-hour battery life. UV cleaning. Background noise cancellation. 45-day risk free trial. Atom X Like us on Facebook advocate newspaper Facebook.com/Advocate.news.ma
20 Publizr Home